There’s a lot of excitement in the weight-loss industry these days. Between Ozempic, Wegovy, Mounjaro, and now Zepbound, investors have been hearing a lot of different names in the industry of late. And there are still more treatments that will likely hit the market in the coming years as healthcare companies fight for market share.
Rather than trying to figure out individual winners, you can simply invest in an exchange-traded fund (ETF). There’s a new one that can give you some great exposure to the weight-loss drug market. The Tema Cardiovascular and Metabolic ETF (NASDAQ:HRTS) has launched this month and it offers a unique opportunity for investors. It is managed by Tema ETFs, and it stands out with its specialized focus on companies involved in the treatment of cardio-metabolic diseases.
The ETF includes 20 to 25 core positions in notable companies, including Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). The fund is actively managed by David Song, a seasoned investor with over 25 years in life-sciences investing. This expert oversight ensures informed decision-making and adaptability to market changes.
For investors uncertain about which specific weight-loss stocks to buy, the Tema Cardiovascular and Metabolic ETF (HRTS) is a compelling investment. With its focused investment approach, expert management, and timely market entry, HRTS is well-positioned to capitalize on the growing demand for treatments addressing obesity and related metabolic conditions.
If you don’t want to worry about picking winners in this fast-growing industry, this could be an ETF worth adding to your portfolio today.
